Paper Details

  1. Home
  2. Paper Details

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Author: BarosiGiovanni, CuneoAntonio, DanesiRomano, FagiuoliStefano, GhiaPaolo, MarzanoAlfredo, MontilloMarco, PolettiVenerino, VialePierluigi, ZinzaniPier Luigi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A consensus document provides practical recommendations for managing side effects during idelalisib therapy for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
Paper Details　
Original Abstract of the Article :
The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585802/

データ提供：米国国立医学図書館（NLM）

Idelalisib: Navigating the Desert of Side Effects

This study focuses on the management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma. It's like navigating a desert of potential side effects, where the journey towards treatment can be fraught with challenges.

Idelalisib: A Powerful Tool with a Price

The study acknowledges the effectiveness of idelalisib, but also highlights the need for careful management of its side effects. It's like a camel caravan that utilizes a powerful beast of burden, but must be vigilant in managing its needs and potential challenges.

Managing Side Effects: A Collaborative Approach

This study emphasizes the importance of a multidisciplinary approach to managing idelalisib-related adverse events. It's like a camel caravan crossing the desert with a diverse group of experts, each contributing their unique skills to overcome challenges and ensure the safety of the journey.

Dr.Camel's Conclusion

This research provides valuable guidance for clinicians treating patients with chronic lymphocytic leukemia and follicular lymphoma who are considering idelalisib therapy. It underscores the importance of proactive management of potential side effects, highlighting the need for a collaborative approach that considers the patient's individual needs.

Date :
  1. Date Completed 2019-03-05
  2. Date Revised 2023-10-12
Further Info :

Pubmed ID

30187496

DOI: Digital Object Identifier

PMC6585802

Related Literature

Article Analysis
・Side Effects of idelalisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.